Study Evaluating Single Ascending Doses Of ILS-920

Wyeth

Status and phase: Completed; Phase 1

Conditions: Acute Ischemic Stroke

Treatments: Drug: ILS-920

Study type: Interventional

Funder types: Industry

Identifiers

NCT00827190

3216K1-1000

Details and patient eligibility

About

This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.

Enrollment: 16 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men or women of nonchildbearing potential
• Aged 18 to 50 years inclusive at screening.

Exclusion criteria

• Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
• History of drug abuse within 1 year before study day 1.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

16 participants in 1 patient group

1

Experimental group

Description:

ILS-920

Treatment:

Drug: ILS-920